Latest news with #LENSAR
Associated Press
19-05-2025
- Business
- Associated Press
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Landsea Homes Corporation (Nasdaq - LSEA), LENSAR, Inc. (Nasdaq - LNSR), AvidXchange Holdings, Inc. (Nasdaq – AVDX), FARO Technologies, Inc. (Nasdaq – FARO)
BALA CYNWYD, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847. There is no cost or financial obligation to you. Landsea Homes Corporation (Nasdaq - LSEA) Under the terms of the agreement, Landsea Homes will be acquired by New Home Co. ('New Home') for $11.30 per share in cash. The investigation concerns whether the Landsea Homes Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. For example, the deal consideration is below the 52-week high of $14.04 for the Company's shares. Additional information can be found at LENSAR, Inc. (Nasdaq - LNSR) Under the terms of the Merger Agreement, LENSAR will be acquired by Alcon for $14.00 per share in cash for each LENSAR share, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash, conditioned on achievement of 614,000 cumulative procedures with LENSAR's products between January 1, 2026, and December 31, 2027. The investigation concerns whether the LENSAR Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company's shareholders are receiving fair value for their shares. Additional information can be found at AvidXchange Holdings, Inc. (Nasdaq – AVDX) Under the terms of the agreement, AvidXchange Holdings will be acquired by TPG (Nasdaq – TPG) for $10.00 a share in cash in a transaction that values AvidXchange Holdings at $2.2 billion. The investigation concerns whether the AvidXchange Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Additional information can be found at FARO Technologies, Inc. (Nasdaq – FARO) Under the terms of the Merger Agreement, FARO will be acquired by AMETEK, Inc. (NYSE - AME) for $44 per share in cash. The investigation concerns whether the FARO Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company's shareholders in the combined company. Additional information can be found at Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Associated Press
15-05-2025
- Business
- Associated Press
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, DNB, BRDG on Behalf of Shareholders
NEW YORK, May 15, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: LENSAR, Inc. (NASDAQ: LNSR)'s sale to Alcon for $14.00 per share in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone. If you are a LENSAR shareholder, click here to learn more about your legal rights and options. Dun & Bradstreet Holdings, Inc. (NYSE: DNB)'s sale to Clearlake Capital Group, L.P. for $9.15 in cash per share. If you are a Dun & Bradstreet shareholder, click here to learn more about your legal rights and options. Bridge Investment Group Holdings Inc. (NYSE: BRDG)'s sale to Apollo. Under the terms of the proposed transaction, Bridge shareholders and Bridge OpCo unitholders will receive, at closing, 0.07081 shares of Apollo stock for each share of Bridge Class A common stock and each Bridge OpCo Class A common unit, respectively. If you are a Bridge shareholder, click here to learn more about your rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 [email protected] [email protected] View original content to download multimedia: SOURCE Halper Sadeh LLP
Yahoo
10-04-2025
- Business
- Yahoo
Is LENSAR (LNSR) a Deeply Undervalued Stock?
Cedar Grove Capital Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned 0.38% in the first quarter compared to -4.27% for the S&P 500 and -9.51% for the Russell 2000. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first quarter 2025 investor letter, Cedar Grove Capital Management emphasized stocks such as LENSAR, Inc. (NASDAQ:LNSR). LENSAR, Inc. (NASDAQ:LNSR) is a commercial-stage medical device company. The one-month return of LENSAR, Inc. (NASDAQ:LNSR) was -6.64%, and its shares gained 325.94% of their value over the last 52 weeks. On April 9, 2025, LENSAR, Inc. (NASDAQ:LNSR) stock closed at $13.63 per share with a market capitalization of $160.703 million. Cedar Grove Capital Management stated the following regarding LENSAR, Inc. (NASDAQ:LNSR) in its Q1 2025 investor letter: "LENSAR, Inc. (NASDAQ:LNSR) was a recent name that we pitched long near the end of February, calling it deeply undervalued and having many characteristics that were ideal for an outsized return in the coming years. A hand using a laser to perform corneal astigmatism surgery. LENSAR, Inc. (NASDAQ:LNSR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 5 hedge fund portfolios held LENSAR, Inc. (NASDAQ:LNSR) at the end of the fourth quarter compared to 5 in the third quarter. In 2024, LENSAR, Inc. (NASDAQ:LNSR) experienced notable revenue growth, with fourth-quarter top-line revenue reaching a record of $16.7 million—marking a 38% increase compared to Q4 2023. While we acknowledge the potential of LENSAR, Inc. (NASDAQ:LNSR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Associated Press
24-03-2025
- Business
- Associated Press
Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating LENSAR (NASDAQ: LNSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon . Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, LENSAR shareholders will receive only $14.00 per share in cash (an aggregate implied value of approximately $356 million*), with an additional non-tradeable contingent value right offering up to $2.75 per share in cash, conditioned on achievement of 614,000 cumulative procedures with LENSAR's products between January 1, 2026, and December 31, 2027. LENSAR insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for LENSAR by imposing a significant penalty if LENSAR accepts a competing bid. We are investigating the conduct of the LENSAR board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Guri Ademi Toll Free: (866) 264-3995 SOURCE: Ademi & Fruchter LLP Copyright Business Wire 2025. PUB: 03/24/2025 09:46 AM/DISC: 03/24/2025 09:47 AM
Yahoo
24-03-2025
- Business
- Yahoo
Alcon Agrees to Acquire LENSAR, Inc.
Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA and ORLANDO, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR's proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon's femtosecond laser-assisted cataract surgery (FLACS) offering. Under the terms of the agreement, Alcon will purchase all outstanding shares of LENSAR for $14.00 per share in cash (an aggregate implied value of approximately $356 million*), with an additional non-tradeable contingent value right offering up to $2.75 per share in cash, conditioned on achievement of 614,000 cumulative procedures with LENSAR's products between January 1, 2026, and December 31, 2027. The total potential consideration of $16.75 per share represents a premium of 24% to LENSAR's 30-day VWAP and a premium of 47% to LENSAR's 90-day VWAP, assuming the milestone is met. The transaction represents a total consideration of up to approximately $430 million*. 'We are excited for the opportunity to bring LENSAR's unique next-generation technologies and intellectual property into our innovative, market-leading equipment portfolio,' said David Endicott, Chief Executive Officer of Alcon. 'By leveraging our global footprint, we have the opportunity to deliver the benefits of advanced femtosecond laser technology to many more surgeons around the world and continue to improve efficiency in cataract surgery.' Currently, there are more than 5 million cataract procedures in the U.S., and approximately 32 million globally.1 FLACS is designed to allow surgeons to utilize a computer-guided laser to address and manage the high prevalence of visually significant astigmatism, perform corneal incisions, capsulotomy, including a refractive capsulotomy, and lens fragmentation, removing the need for blade incisions. This can contribute to more precise, reproducible and reliable cataract surgery. 'Our focus has been on providing surgeons with breakthrough laser technology in cataract surgery for today and tomorrow,' said Nick Curtis, Chief Executive Officer of LENSAR. 'Thanks to the continued passion and commitment of LENSAR associates, customers and our investors, we are excited about the potential Alcon has to advance the industry in next-generation laser technology for refractive cataract surgery, furthering our and their mission to meet the needs of both surgeons and their cataract patients.' The transaction is anticipated to close in mid-to-late 2025, subject to customary closing conditions, including regulatory approval and approval by LENSAR's stockholders. Lazard is serving as financial advisor to Alcon, and Norton Rose Fulbright is serving as legal advisor to Alcon. Wells Fargo is serving as financial advisor to LENSAR and Latham & Watkins LLP is serving as legal advisor to LENSAR. Forward-looking StatementsThis press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the potential transaction between Alcon and LENSAR and the expected timing, impacts and benefits thereof, Alcon's and LENSAR's business strategies, performance, market adoption and usage. In some cases, you can identify forward-looking statements by terms such as 'aim,' 'anticipate,' 'approach,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'look,' 'may,' 'mission,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'pursue,' 'should,' 'target,' 'will,' 'would,' or the negative thereof and similar words and expressions. Forward-looking statements are based on Alcon's and LENSAR's management's current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions. The following factors could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: (i) the proposed merger may not be completed in a timely manner or at all, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect LENSAR or the expected benefits of the proposed merger or that the approval of LENSAR's stockholders is not obtained; (ii) the failure to realize the anticipated benefits of the proposed merger; (iii) the possibility that competing offers or acquisition proposals for LENSAR will be made; (iv) risks that the milestone related to the contingent value rights is not achieved; (v) the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger, including in circumstances which would require LENSAR to pay a termination fee or other expenses; (vii) the effect of the announcement or pendency of the merger on LENSAR's ability to retain and hire key personnel, or its operating results and business generally, (viii) there may be liabilities related to the merger that are not known, probable or estimable at this time or unexpected costs, charges or expenses; (ix) the merger may result in the diversion of management's time and attention to issues relating to the merger; (x) there may be significant transaction costs in connection with the merger; (xi) legal proceedings may be instituted against LENSAR following the announcement of the merger, which may have an unfavorable outcome; and (xii) LENSAR's stock price may decline significantly if the merger is not consummated. In addition, a number of other important factors could cause LENSAR's actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to those important factors discussed under the heading 'Risk Factors' contained in Alcon's Annual Report on Form 20-F for the fiscal year ended December 31, 2024 and in LENSAR's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, each as filed with the Securities and Exchange Commission ('SEC'), as such factors may be updated from time to time in such company's other filings with the SEC, accessible on the SEC's website at and the Investor Relations section of LENSAR's website at and Alcon's website at All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, neither Alcon nor LENSAR undertake any obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing Alcon's or LENSAR's views as of any date subsequent to the date of this press release. About AlconAlcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at About LENSARLENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR's advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR's proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes. Learn more at Additional InformationThis press release may be deemed solicitation material in respect of the proposed acquisition of LENSAR. A special stockholder meeting will be announced soon to obtain stockholder approval in connection with the proposed merger. LENSAR expects to file with the SEC a proxy statement and other relevant documents in connection with the proposed merger. Investors of LENSAR are urged to read the definitive proxy statement and other relevant materials carefully and in their entirety when they become available because they will contain important information about the Company and the proposed merger. Investors may obtain a free copy of these materials (when they are available) and other documents filed by LENSAR with the SEC at the SEC's website at and at LENSAR's website at Participants in the SolicitationLENSAR and its directors, executive officers and certain other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of LENSAR's stockholders in connection with the proposed merger will be set forth in LENSAR's definitive proxy statement for its special stockholder meeting. Additional information regarding these individuals and any direct or indirect interests they may have in the proposed merger will be set forth in the definitive proxy statement when and if it is filed with the SEC in connection with the proposed merger. References 2025 Market Scope Data. Alcon Investor RelationsDaniel Cravens, Allen Trang+ 41 589 112 110 (Geneva)+ 1 817 615 2789 (Fort Worth) Alcon Media RelationsSteven Smith+ 41 589 112 111 (Geneva)+ 1 817 551 8057 (Fort Worth) LENSAR Investor RelationsThomas R. Staab, II, LENSAR Media RelationsLee Roth / Cameron RadinovicBurns McClellan for LENSARlroth@ / cradinovic@ _________________________________________ * Assuming use of the Treasury Stock Method
